Dextromethorphan + Dimebon + Dextromethorphan
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Huntington Disease
Conditions
Huntington Disease, Alzheimer Disease
Trial Timeline
Nov 1, 2008 → Jan 1, 2009
NCT ID
NCT00788047About Dextromethorphan + Dimebon + Dextromethorphan
Dextromethorphan + Dimebon + Dextromethorphan is a phase 1 stage product being developed by Pfizer for Huntington Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00788047. Target conditions include Huntington Disease, Alzheimer Disease.
What happened to similar drugs?
1 of 11 similar drugs in Huntington Disease were approved
Approved (1) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00788047 | Phase 1 | Completed |
Competing Products
20 competing products in Huntington Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + Matching Placebo | Eli Lilly | Phase 2 | 35 |
| Votoplam (blinded) + Placebo | Novartis | Phase 3 | 47 |
| Votoplam | Novartis | Phase 2 | 39 |
| Branaplam + Placebo | Novartis | Phase 2 | 27 |
| AFQ056 + Placebo | Novartis | Phase 2 | 27 |
| RO7234292 (RG6042) | Roche | Phase 1 | 29 |
| Tominersen + Placebo | Roche | Phase 2 | 39 |
| RO7234292 (RG6042) | Roche | Phase 3 | 40 |
| RO7234292 (RG6042) | Roche | Phase 2 | 35 |
| RG6496 + Placebo | Roche | Phase 1 | 36 |
| RO7234292 + Placebo | Roche | Phase 3 | 40 |
| PF-02545920 + PF-02545920 | Pfizer | Phase 2 | 35 |
| Dimebon | Pfizer | Phase 3 | 40 |
| Dimebon (latrepirdine) | Pfizer | Phase 3 | 32 |
| 20 mg BID of PF-02545920 | Pfizer | Phase 2 | 27 |
| PF-02545920 + Placebo + PF-02545920 + Placebo | Pfizer | Phase 2 | 35 |
| Riluzole | Sanofi | Phase 3 | 40 |
| ALN-HTT02 + Placebo | Alnylam Pharmaceuticals | Phase 1 | 33 |
| Tetrabenazine | Lundbeck | Approved | 36 |
| Valbenazine | Neurocrine Biosciences | Phase 3 | 41 |